Tetrous Surpasses 5,500 EnFix Implants Marking Significant Milestone
News related to:Tetrous, Inc · 2 min read
LOS ANGELES, Oct. 13, 2026 /CourierPR/ -- Tetrous, Inc., an emerging leader in orthopedic sports medicine innovation, has announced that more than 5,500 EnFix® demineralized bone fiber (DBF) devices have been implanted since the product's commercial launch. This milestone, achieved approximately two years after the full commercial launch, reflects growing surgeon adoption and expanding use of EnFix across orthopedic sports medicine applications.
The EnFix portfolio includes EnFix RC®, EnFix TAC-O®, EnFix TAC-T®, and EnFix ACL® and is designed for placement within bone at the site of soft tissue attachment, supporting the body's natural healing response at the bone-tendon interface. Tetrous began a controlled commercial launch of EnFix in the United States and Australia in July 2023 with seven surgeons. Since then, the company has experienced significant growth in surgeon adoption, clinical applications, geographic reach, and has achieved key milestones.
Tetrous has expanded beyond the United States and Australia into New Zealand and Puerto Rico. The company has also grown its portfolio to address an expanding range of orthopedic soft tissue repair applications. The EnFix family of demineralized bone fiber implants, including EnFix RC®, EnFix TAC® and EnFix ACL®, are designed to enhance the natural healing response by supporting biologic reformation at the bone-to-tendon junction. By focusing on clinically validated technologies that reduce failure rates, accelerate recovery, and restore function, Tetrous is helping surgeons achieve consistent, evidence-based results that translate into both short-term return to normal activities and long-term positive outcomes for patients.
Unlike augmentation approaches placed on top of the tendon, EnFix is designed specifically for placement within bone at the bone-tendon interface. The implant is manufactured to preserve and expose the DBF's naturally occurring bone morphogenetic proteins (BMPs), which help guide the body's cellular response and support the natural healing process.
The EnFix family of products includes EnFix RC®, EnFix TAC-O®, EnFix TAC-T®, and EnFix ACL®. Tetrous, Inc., founded in 2019, utilizes next-generation advanced technologies for enthesis repair in sports medicine applications. The company enjoys significant IP protection for its EnFix family of products with multiple issued patents and, additionally, has an exclusive license to the demineralized bone fiber technology used in its products for sports medicine applications from TheraCell, an ISTO Biologics Company.